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EMicroRNA-503 and the Extended
MicroRNA-16 Family in Angiogenesis
Andrea Caporali and Costanza Emanueli*
MicroRNAs (miRs) are post-transcriptional inhibitory regulators of
gene expression acting by direct binding to complementary messenger
RNA (mRNA) transcripts. Recent studies have demonstrated that miRs
are crucial determinants of endothelial cell behavior and angiogenesis.
We have provided evidence of the prominent role of miR-503 in
impairment of postischemic reparative angiogenesis in the setting
of diabetes. Because miR-503 belongs to the miR-16 extended family
of miRs, in this review, we describe the cardiovascular functions of
miR-503 and other members of the miR-16 family and their impact
on angiogenesis. (Trends Cardiovasc Med 2011;21:162-166) © 2011m
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f• Introduction
MicroRNAs (miRs) are small, noncoding
RNAs that regulate gene expression,
mainly by binding 3’ untranslated re-
gions (3’ UTRs) of messenger RNA
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at the Laboratory of Vascular Pathology and
Regeneration, School of Clinical Sciences,
University of Bristol, Bristol BS2 8HW, UK.
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© 2011 Elsevier Inc. All rights reserved.(mRNA) transcripts. Regulation of miRs
is an emerging feature in developmental
biology, cancer, and cardiovascular dis-
ease (Sayed and Abdellatif 2011). miRs
are predicted to target more than 50% of
all human protein-coding genes, thus
inducing translational repression, mRNA
degradation, or mRNA instability. He-
nce, accurately determining miR targets
is essential for understanding the func-
tional roles of miR in physiology and
diseases.
Blood vessel formation by angiogen-
esis is a complex multistep process that
requires control and coordination of en-
dothelial cell (EC) behavior as well as sthe contribution of pericytes and other
intra- and extravascular supportive cells.
Commonly recognized as “cell embed-
ded within the vascular basement mem-
brane” and identified by several mole-
cular markers (alpha smooth muscle
actin, nonmuscle myosin, tropomyosin,
desmin, nestin, platelet-derived growth
factor receptor- [PDGFR-], amino-
eptidases A and N [CD13], sulfatide,
nd nerve/glial antigen-2 proteoglycan
Díaz-Flores et al. 2009]), pericytes play
n essential role in the stabilization and
aturation of new vascular networks.
DGF-B, released from ECs undergoing
ngiogenic remodeling, acts as a che-
oattractant for comigrating pericytes
hat express PDGFR-. Recruited peri-
ytes are incorporated into the wall of
mmature vessels and establish direct
ell-cell contact with ECs. Interactions
ccurring between pericytes and ECs are
trengthened by several molecules, such
s transforming growth factor- (TGF-
), vascular endothelial growth factor
VEGF), and angiopoietins, and by sig-
aling pathways involving Notch and
phrins (Armulik et al. 2011).
In stable vessels, ECs typically form a
onolayer of quiescent cells that lines
he luminal surface of vascular tubes. In
esponse to proangiogenic stimuli, ECs
oosen their cell-cell contacts, activate
roteases that degrade the surrounding
asement membrane, and acquire exten-
ively invasive and motile behavior to
nitiate new blood vessel sprouting, fol-
owed by further vascular morphogene-
is and maturation (Potente et al. 2011).
merging evidence suggests that miRs
ight contribute to the fine-tuning of
he genes involved in the angiogenic
rocess.
Disrupted balance of angiogenesis
ontributes to the pathogenesis of nu-
erous disease states (Carmeliet and
ain 2011). For example, uncontrolled
ngiogenesis favors tumor growth and
etastasis. Although it is desirable to
lock the growth of new blood vessels
n these circumstances, the controlled
timulation of angiogenesis is beneficial
n ischemic conditions, characterized by
mpaired local blood supply. Consider-
ng the potential clinical benefits of ther-
peutically manipulating blood vessel
rowth and blood flow, the mechanisms
egulating the angiogenetic process have
ormed a major focus for vascular re-
earch during the past two decade.
TCM Vol. 21, No. 6, 2011
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m• miR-503 Belongs to the miR-16
Family
The 5’-end portion (5’ UTR) of miRs, also
known as the “seed region,” is a partic-
ularly important determinant of miR
function (Lewis et al. 2005). miRs with
the sequence AGCAGC (AGCx2), starting
at the second nucleotide from the 5’ end
of their mature form, belong to the “ca-
nonical” miR-16 family. Members of this
family are miR-15a/b, miR-16, miR-195,
miR-424, and miR-497. Moreover, based
on the presence of AGCx2 motif starting
at the first nucleotide in seed sequence,
miR-103, miR-107, and miR-646 could
be also included in an “extended”
miR-16 family (Finnerty et al. 2010). The
seed region of miR-503 differs only at
nucleotide 8 from the seed region of the
canonical miR-16 family: This nucleo-
tide is a guanosine in miR-503 and an
adenosine in the miR-16 family. This
leads to an overlap between target genes
because 8-mer sites (positions 2-8 of the
mature miR followed by an “A”) for
miR-503 are recognized as 7-mer-A1
(positions 2-7 of the mature miR fol-
lowed by an “A”) sites by canonical
miR-16 family members and vice versa
(Rissland et al. 2011) (Table 1). In agree-
ment with the knowledge that the
Table 1. Sequences of the mature
miRs
First nucleotide of t
mature miR sequen
hsa-miR-15a U
hsa-miR-15b U
hsa-miR-16 U
hsa-miR-195 U
hsa-miR-503 U
hsa-miR-424 C
hsa-miR-497 C
a Note that the last nucleotide of the seed reg
Table 2. Extended miR-16 family i
miRNAs Identified target gen
miR-15b Pdk4, Sgk1
miR-16 VEGFR2, FGFR1, VE
miR-103/107 Caveolin-1
miR-195/497 ELN, Col1a1, Col1a2
miR-195 Unknown
Check1
miR-424 CUL2
VEGFR2, FGF-R1, V
MEK, CCNE1iR-503 CCNE1, cdc25A
TCM Vol. 21, No. 6, 2011AGC2x motif near the miRs’ 5’ end con-
trols the miR target specificity, there is
evidence that different members of the
miR-16 family, including miR-503, reg-
ulate overlapping miR targets (Forrest et
al. 2010, Joglekar et al. 2007).
miR-503 is an intragenic miRNA clus-
tered with miR-424 on chromosomal lo-
cation Xq26.3 (Griffiths-Jones et al.
2008). miR-424 has been implicated in
regulation of angiogenesis (Ghosh et al.
2010, Chamorro-Jorganes et al. 2011).
miR-503 and miR-424 are separated by
383 bases on the genome and are likely
derived from the same primary tran-
script as a pair of hairpins and to have
related seed sequences. A further five
miRs (miR-542-5p, miR-542-3p, miR-
450a, miR-450b-5p, and miR-450b-3p)
are within 7 kb of the miR-424–miR-503
cluster and can be transcribed from the
same primary transcript. It is not known
if these additional five miRs are ex-
pressed in vascular cells or involved in
angiogenesis. Members of the miR-16
family are also intragenic miRNA and
expressed from different loci as pairs of
hairpins, closely spaced with linker re-
gions of 150-200 nucleotides.
Considering the seed sequence simi-
larities and the genomic organization, it
rms of miRs belonging to the exten
Seed common
region
Last nu
the see
AGCAGC A
AGCAGC A
AGCAGC A
AGCAGC A
AGCAGC G
AGCAGC A
AGCAGC A
is a G only for miR-503.
ascular biology and diabetes
Stimuli inducing miR expressi
upregulation
Myocardial infarction
F VEGF-A, bFGF
Type 2 diabetes
Aortic development
Cardiac hypertrophy
Heart development
Ischemia
F VEGF-A, bFGF
Hemangioma
Diabetes  critical limb ischemiais possible to classify miR-503 as part of
the extended miR-16 family (Table 2).
• miR-503 Expression and Functions
miR transcription is controlled through
the same regulatory machinery as for
the protein coding genes (Lee et al.
2004). Understanding the mechanisms
regulating the activation or repression of
miR transcription requires locating their
core promoter regions using promoter
prediction methods (Zhou et al. 2007).
Moreover, Marson et al. (2008) found
that the transcription starting sites
(TSSs) within the promoter regions of
miRs are determined by the presence of
trimethylated histone H3 at its lysine 4
residue (H3K4me3). Using bioinfor-
matic approaches, including the extrac-
tion of promoter regions for miR genes,
computational prediction of transcrip-
tion factor binding sites (TFBSs) to es-
tablish TFs/miR associations, and the
use of time course expression data for
TFs and miRs, Schmeier et al. (2009)
identified the following TFs that bind in
the promoter region of miR-424:
RUNX1, E2F3, SP3, YY1, NFE2L2,
CREB1, ATF2, USF2, ELK1, CEBPB,
and HOXA4. Because pre-miR-503 is
transcribed together with pre-miR-424
as one transcript, it is likely that miR-
d miR-16 familya
otide of
equence
End of the mature
miR sequence
CAUAAUGGUUUGUG
CAUCAUGGUUUACA
CGUAAAUAUUGGCG
CAGAAAUAUUGGCC
GGAACAGUUCUGCAG
AUUCAUGUUUUGAA
C ACUGUGGUUUGU
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1503 expression is subjected to the same
transcriptional regulation of miR-424.
The mechanisms of miR-503 transcrip-
tion and maturation have not yet been
demonstrated, and more “wet” experi-
ments are needed to verify this hypoth-
esis.
miR-503 was first identified in human
retinoblastoma tissues using the miR
microarray technique (Zhao et al. 2009).
Moreover, miR-503 expression was
found upregulated in human parathy-
roid carcinomas (Corbetta et al. 2010)
and in adenocortical carcinomas (Töm-
böl et al. 2009)). In monocytes differen-
tiating toward macrophages, miR-424
and miR-503 are produced as a polycis-
tronic message and induce G1 arrest by
targeting an overlapping set of cell cycle
regulators (Forrest et al. 2010). In line
with this, induction of G1 phase cell
cycle arrest is critical for the differenti-
ation of myoblasts into myotubes. More-
over, miR-424 and miR-503 are induced
during myogenesis and promote cell cy-
cle arrest through cdc25A degradation
(Sarkar et al. 2010). Hence, these two
miRs appear to be part of the differenti-
ation processes. In addition, miR-503
expression increases in response to se-
rum starvation in mesenchymal stem
cells (Nie et al. 2011), NIH-3T3 cells
(Rissland et al. 2011), and ECs cultured
in high glucose (Caporali et al. 2011).
Interestingly, in NIH-3T3 G1 arrested by
serum starvation, miR-503 returns to
normal level upon cell cycle reentry
(Rissland et al. 2011). miR-503 expres-
sion is also upregulated in response to
growth arrest by cell contact inhibition.
Rapid degradation during cell cycle re-
entry of miR-503 is dependent on its
constitutive instability. Thus, miR-503
modulates the cell cycle and is itself
dynamically regulated by the cell cycle.
Increased miR-503 in human umbili-
cal vein ECs and human microvascular
ECs results in cell cycle delay in G1,
reduced cell proliferative and migratory
capacity, and impaired EC networking
capacities, suggesting an anti-angio-
genic role for this miR (Caporali et al.
2011).
In vivo, miR-503 is upregulated in
myocardial ECs from diabetic GK rats
(Wang et al. 2009) and in ECs resident in
ischemic limb muscles of diabetic mice
(Caporali et al. 2011). It is also upregu-
lated in ischemic limb skeletal muscles
and plasma of diabetic patients with (
164end-stage critical limb ischemia (Capo-
ali et al. 2011).
miR-503 Validated Target Genes
ecent studies have proposed that miR-
03 might be a master regulator of the
ell cycle (Rissland et al. 2011). Gene
ntology analysis of genes affected by
iR-503 identified those annotated as
ell cycle regulators or involved in cell
dhesion, migration, and angiogenesis
rocesses (Caporali et al. 2011). Using
rediction software, four genes were
onsistently identified as targets of miR-
03: cell division cycle 25A (CDC25A),
yclin D1 (CCND1), cyclin D2 (CCND2),
nd cyclin E1 (CCNE1). By 3’ UTR-lucif-
rase assays, we validated CDC25A and
CNE1 as direct target genes of miR-503
Caporali et al. 2011). CCND1 and
CND2 were validated as miR-503 tar-
ets by others (Jiang et al. 2009). The
oncept of miR-503 being involved in
he cell cycle process has been further
nforced by the finding of Forest et al.
2010) that mir-503 inhibits the expres-
ion of additional genes involved in cell
ivision, the cell cycle, and mitosis, such
s CCNE, CCNF, CDC14A, anillin, acti-
ating transcription factor 6 (ATF6), Ar-
onaute 1 (Ago1), checkpoint kinase 1
CHEK1), mitosis inhibitor protein ki-
ase WEE1, and CDKN1A (p21). Seven
f these targets are in common with
iR-424 (Forrest et al. 2010). Interest-
ngly, cell cycle genes involved in G1-S
ransition, such as CCDN1, CCNE1, and
dc25A, are targeted by most of the
embers of the extended miR-16 family
Liu et al. 2008, Rissland et al. 2011).
orrest et al. also showed that an in-
rease in miR-503 downregulates miR-
-3, thus demonstrating reciprocal ex-
ressional regulation between miRs
Forrest et al. 2010). Because miRs can
egulate other miRs, these interactions
ncrease the complexity of gene regula-
ion and are likely to be involved in
egulatory processes that are currently
nexplored.
Extended miR-16 Family in
Vascular Biology and Diabetes
hosh et al. (2010) reported that miR-
24 is induced by hypoxia in ECs and
romotes angiogenesis in vivo and in
itro through PU.1-dependent transacti-
ation and direct inhibition of cullin 2
CUL2), which increase HIF-1 levels. Inontrast, Chamorro-Jorganes et al.
2011) demonstrated that overexpres-
ion of miR-424 or miR-16 reduces pro-
iferation, migration, and angiogenic ca-
acity of ECs in vitro and in a Matrigel
lug implanted in mice. In agreement
ith the findings of Chamorro-Jorganes
t al., miR-424 expressional inhibit-
on using oligos anti-miR in human der-
al microvascular ECs abnormally in-
reases cell proliferation and promotes
ngiogenesis, possibly via increased levels
f MEK1 or CCNE1 (Nakashima et al.
010). Moreover, miR-424 and miR-16 re-
uce the expression of VEGF-A, VEGF
eceptor 2 (VEGFR2), and fibroblast
rowth factor receptor 1 (FGF-R1) by
inding at 3’ UTR sequences (Chamorro-
organes et al. 2011, Musumeci et al.
011). Interestingly, either VEGF-A or ba-
ic FGF (bFGF) treatment upregulates ex-
ression of mature miR-16 and miR-424;
hus, a regulatory loop between miR-16,
iR-424, and the major proangiogenic
rowth factors exists. miR-16 is tran-
cribed together with either miR-15a
miR-15a/-16-1 cluster) or miR-15b (miR-
5b/-16-2 cluster). In line with data from
hamorro-Jorganes et al., we found that
iR-16 and miR-15a are upregulated in
roangiogenic circulating cells (PACs;
reviously known as endothelial progeni-
or cells) of patients with critical limb
schemia and that increased miR-15/16
mpairs PAC functional capacities (Fortu-
ato et al. 2012). Moreover, miR-15a,
iR-15b, miR-16-1, miR-16-2, miR-424,
nd miR-497 were consistently found to
e upregulated in cardiomyocytes during
ardiac ischemia and heart failure (re-
iewed in Small et al. 2010). Hullinger et
l. (2012) demonstrated that systemic in-
ibition of miR-15 by locked nucleic acid–
odified anti-miRs reduces infarct size
nd cardiac remodeling and enhances car-
iac function in response to myocardial
nfarction inmice. Cardiac expression and
unction are also described for another
iR-16 family member, miR-195, which
s upregulated during cardiac hypertro-
hy. Moreover, mice overexpressing miR-
95 under the -myosin heavy chain
promoter develop fatal dilated car-
diomyopathy (van Rooij et al. 2006).
Recently, miR-195 was shown to be the
most expressed miR in the heart between
postnatal days 1 and 10. In particular,
miR-195 is associated with cardiomyocyte
postmitotic arrest due to the inhibition of
several genes involved in cell cycle pro-
TCM Vol. 21, No. 6, 2011
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rgression (Porrello et al. 2011). Further-
more, miR-195 and miR-497 are upregu-
lated during aortic development, with
subsequent downregulation of their target
genes, including elastin (ELN), collagen
1a1 (Col1a1), and collagen 1a2 (Col1a2)
(Ott et al. 2011) (Table 2). Finally, miR-
03 and miR-107 are negative regulators
f insulin sensitivity and may contribute
o the etiology of diabetes. Moreover,
lobal miR-103/107 silencing causes in-
reased insulin signaling in both liver and
dipose tissue (Trajkovski et al. 2011).
Direction of Future Research
ysfunction of the blood vascular endo-
helium is a major factor in the patho-
enesis of micro- and macroangiopathy.
estoring EC function is fundamental in
eestablishing vessel integrity and main-
aining tissue perfusion. In the develop-
ent of novel therapies aimed at pre-
erving the EC layer and promoting
eparative angiogenesis, the first chal-
enge is to find a combination of factors
ble to prevent EC apoptosis and im-
rove EC functional capacities. To
chieve this, the regulation of gene net-
orks should play a fundamental role.
n this context, regulation of specific
iRs or an entire family of miRs and
onsequently modulation of their target
enes could lead to novel therapeutic
pproaches. In our study on miR-503,
e showed the first example of a miR-
ased intervention normalizing post-
schemic reparative angiogenesis in
iabetes. We demonstrated that antago-
izing miR-503 using adenovirus-medi-
ted local delivery of a competitive in-
ibitor (an miR-503 decoy) improved
ostischemic reparative neovasculariza-
ion and blood flow recovery and re-
tored expression of miR-503 target
enes (Caporali et al. 2011). Because
iR-15a, -15b, -16, -195, -424, -497, and
503 regulate overlapping lists of miR
argets due to similarity in seed se-
uence, inhibition of the entire family of
iRs could lead to a further benefit
ostischemic revascularization, includ-
ng in diabetic patients.
However, the most advanced ap-
roach currently used to regulate miR
evels in vivo is the use of anti-miRs.
nti-miRs are modified antisense oli-
odeoxynucleotides harboring the full or
artial complementary reverse sequence
f a mature miR. These oligodeoxy-
ucleotides are able to reduce the endog-
TCM Vol. 21, No. 6, 2011nous levels of the miR, thus increasing
xpression of its mRNA targets. Re-
ently, anti-miR technology has been
sed for miR-15 inhibition in the setting
f ischemic heart disease (Porrello et al.
011), and preclinical studies are ongo-
ng at miRagen Therapeutics (http://
ww.miragentherapeutics.com) with
he aim to commercialize an miR-15
nhibitor for the treatment of cardiovas-
ular disorders.
Although there has been a significant
ncrease in the number of patent appli-
ation filings during the past 10 years
nd great excitement surrounding miRs
s novel drugs, only one anti-miR com-
ound has been included in clinical tri-
ls: Anti-miR-122 has been used to treat
iver disease caused by hepatitis C virus
http://www.santaris.com). Further
tudies are necessary to clarify any “off-
arget” effect of miRs inhibitors, which
ay need to be addressed in order to fill
he bench-to-bedside gap.
Finally, the discovery of miRs in bio-
ogical fluids and the hypothetical possi-
ility use of miRs as clinical diagnostic
nd prognostic biomarkers is an hot
opic in the miR field. Further investiga-
ions of miR-503 as a possible biomarker
or peripheral artery disease (PAD) in
iabetic subjects are required. We plan
o investigate the predictive potential of
irculating miR-503 for leg ischemia in
AD patients. Larger numbers of pa-
ients and correlations with clinical out-
omes need to be analyzed. Further-
ore, measuring the level of other
iR-16 family members in PAD patients
ithout diabetes could help in the pre-
iction of limb ischemia.
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Hypertension
Rasa Tamosiuniene and Mark R. Nicolls*
Pulmonary hypertension (PH) is a disease of high lethality arising from
numerous causes. For a significant subset of PH patients, autoimmune
biomarkers or frank autoimmune disease are simultaneously present,
but the extent to which lung inflammation contributes to PH ismental and clinical evidence sug-ests that immune dysregulation
ay lead to the propagation of
ascular injury and PH. A recent
reclinical study demonstrated
hat regulatory T cells are impor-
ant mediators normally enlisted
o control inflammation and that,
f absent or dysfunctional, may
redispose to the development of
H. (Trends Cardiovasc Med
011;21:166-171) Published by• Introduction
For more than 50 years, it has been
recognized that autoimmune phenom-
ena are associated with certain forms of
pulmonary hypertension (PH), but it has
never been previously demonstrated that
immune dysregulation may be a root
cause for PH. To address this issue, our
group recently demonstrated how im-
mune dysregulation exacerbates vascu-
lar inflammation and results in severe
PH (Tamosiuniene et al. 2011). In this
experimental model, athymic (T cell–
deficient) rats developed significant
pulmonary vascular disease following
treatment with SU5416, a vascular endo-
thelial growth factor-2 (VEGFR-2) in-
hibitor. The main finding of this study
was that PH may arise when the absence
of normal anti-inflammatory regulatory
T cell (Treg) activity results in a failure
to control inflammatory endothelial in-
jury. Restoring Tregs to these animals,
prior to vascular injury, prevents the
development of PH. The relevant clinical
parallel is that a number of diseases
associated with PH are, like the athymic
rat, associated with conditions having
abnormal Treg numbers or activity (re-
viewed in Nicolls et al. 2005). The pur-
poses of this review are to discuss the
findings of the study by Tamosiuniene et
al. (2011), to put into context what is
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